Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients

NCT01489566 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular,Carcinoma

Interventions

DRUG: Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )
DRUG: the placebo ,chemotherapy(mitomycin, and Fluorouracil )

Sponsor

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Collaborators

[object Object]
[object Object]